Here are four things to know.
- Neulasta, which earned about $4.6 billion in sales last year, is used to treat infections in cancer patients.
- The biosimilar represents one of Coherus’ lead experimental drugs, according to Reuters.
- Upon notification of the rejection, the FDA asked the drugmaker to reanalyze data and provide additional manufacturing information, according to the report.
- Coherus said it plans to work with the agency to address its concerns.
More articles on supply chain:
Bristol-Myers susceptible to acquisition following failed cancer trial, investors say
FDA approves Qiagen’s TB blood test: 3 things to know
7% of cancer patients say pharma prices drugs fairly: 5 survey findings
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
